

Rec'd PCT/PTO 16 JUN 2005

#4

PATENT

UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: BERNHARDT ET AL 2 PCT

SERIAL NO: 10/512,737 CONF. # 1552

PCT SERIAL #: PCT/EP03/03973

PCT FILING DATE: APRIL 16, 2003

TITLE: TRANSPORT SYSTEM IN BIOLOGICAL SYSTEMS

INFORMATION DISCLOSURE STATEMENT

Mail Stop: PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants wish to bring to the attention of the Patent Examiner the (11) references listed on the enclosed Form PTO-1449 and attached thereto.

The reference: "Nunez, M., Saballs, P., Valencia, ME., Santos, J., Ferrer, E., Santos, I., Berrocal, A., Galindo, MJ., Podzamczner, D., Gonzalez-Lahoz, J. 2001. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy. HIV Clin. Trials. 2(5):429-37.)" discussed in the present Specification on page 3, in the first paragraph, is enclosed.


The references cited in the 1st Austrian Office Action are also enclosed.

Since this Information Disclosure Statement is being filed prior to a first Office Action, it is believed that no fee is due. However, if it is determined that a fee is due, the Commissioner is hereby authorized to charge, or to credit any over payment, to our Deposit Account Number 03-2468.

It is respectfully requested that this Information Disclosure Statement be considered and placed into the application file.

Respectfully submitted,

Jürgen BERNHARDT ET AL 2 PCT


Allison C. Collard, Reg. No. 22,532
Frederick J. Dorchak, Reg. No. 29,298
Edward R. Freedman, Reg. No. 26,048
Attorneys for Applicants

COLLARD & ROE, P.C.
1077 Northern Boulevard
Roslyn, New York 11576
(516) 365-9802

Enclosures: 1) PTO-form 1449 w/copies of references
 2) Copy of International Search Report

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: COMMISSIONER OF PATENTS, P.O. Box 1450, Alexandria, VA 22313-1450 on JUNE 14, 2005.


Maria Guastella

FORM PTO-1449 (Modified) (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: BERNHARDT ET AL 2 PCT	SERIAL NO.: 10/512,737
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT: Jürgen BERNHARDT ET AL	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AD	WO 99 33493	7/1999	International (Intl. Srch. Rep.)				
	AE	EP 0 497 997	8/1996	European (Intl. Srch. Rep.)				
	AF	WO 01 60848	8/2001	International (Intl. Srch. Rep.)				
	AG	WO 98/02454	1/1998	International (encl. German Office Action)				
	AH	WO 95/31183	11/1995	International (encl. Austrian Office Action)				
	AI	JP6219967	8/1994	Japan (encl., w/abstract Austrian Office Action)				
	AJ	WO 90/07924	7/1990	International (encl. Austrian Office Action)				
	AK	WO 97/41834	11/1997	International (encl. Austrian Office Action)				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AL		LESTINI B J ET AL: "Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery" JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.B. AMSTERDAM, NL, vol. 78, no 1-3. 17 January 2002, pages 235-247, XP004329821 (Intl. Srch. Rep.)
	AM		Database SWALL 'Online! EBI; 1 October 1996 "CAD4_Human" retrieved from WWW.EBI.AC.UK Database accession no. P55283 XP002255166, abstract. (Intl. Srch. Rep.)
	AN	✓	Nunez, M., Saballs, P., Valencia, ME., Santos, J., Ferrer, E., Santos, I., Berrocal, A., Galindo, MJ., Podzamczar, D., Gonzalez-Lahoz, J. 2001. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy. HIV Clin. Trials. 2(5):429-37.) ENCLOSED

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.